GHIT Fund is an international public-private partnership fund for global health research and development that mobilizes Japanese industry, academia, and research institutes to create new drugs, vaccines, and diagnostics for malaria, tuberculosis, and neglected tropical diseases.

GHIT Fund

Global Health Innovative Technology (GHIT) Fund | 2,927 followers on LinkedIn. The Global Health Innovative Technology Fund (GHIT Fund), headquartered in Japan, is an international public-private partnership between the Government of Japan (Ministry of Foreign Affairs and Ministry of Health, Labour and Welfare), seven Japanese pharmaceutical and diagnostics companies (Astellas, Chugai, Eisai, Daiichi Sankyo, Shionogi, Sysmex and Takeda), the Bill &amp; Melinda Gates Foundation, Wellcome Trust, and United Nations Development Programme. GHIT funds scientific research and development for anti-infectives and diagnostics for diseases that primarily affect the developing world. GHIT is the first public-private partnership fund to involve a national government, a UN agency, a consortium of pharmaceutical and diagnostics companies, and international philanthropic foundations.

Product Development and Clinical Laboratory Operations Consultant at Halteres Associates

Paul Jorgensen

Lecturer on Law at Harvard Law School

Ko-Yung Tung

Investment Strategy, Portfolio Development & Innovations

Kiichiro Kobori

Public Health Specialist at Ministry of Health, Labour and Welfare of Japan

Hiroki Nakatani

Global Health Innovative Technology (GHIT) Fund

👏Fantastic to see this announcement of approximately JPY 578m (US$4m) of investment from Global Health Innovative Technology (GHIT) Fund in projects developing new diagnostics and drugs for neglected tropical diseases (NTDs) and malaria. Projects the funding will focus on include trachoma, the first time the Fund has provided investment targeting this NTD, as well as Chagas disease, exploring the development of rapid diagnostic tests to support with early detection and appropriate treatment. With the World Health Organization (WHO) target to eliminate trachoma and Chagas disease as a public health problem by 2030, the investment will help towards reaching these goals, with rapid and accurate diagnosis critical in achieving these targets. Thank you Japan for demonstrating your commitment to #BeatNTDs . Read GHIT Fund's press release to find out more about the projects: https://lnkd.in/gfh9Zc6y

Uniting to Combat Neglected Tropical Diseases

ブラジルはどのように感染症と闘ってきたか？ その歩みから学ぶこと CEOの國井によるブラジルとグローバルヘルスのストーリーです。 ぜひご一読ください。

[Press Release📢] The GHIT Fund announced today a total investment of approximately JPY 578 million (USD 4.0 million) in four projects for the development of new diagnostics and drugs for neglected tropical diseases ( #NTDs ) and #malaria . The GHIT Fund has decided to invest approximately JPY 280 million (USD 2.0 million) in a project led by US-based non-profit organization Drugs & Diagnostics for Tropical Diseases (DDTD), in collaboration with Medical & Biological Laboratories, Co. Ltd. (MBL) in Japan, The Carter Center (TCC, USA) , and Big Eye Diagnostics , Inc. (BEDx, USA), with active support from the Centers for Disease Control and Prevention (CDC), to develop a Rapid Diagnostic Test (RDT) kit for #trachoma . This is the first time for the GHIT Fund to support product development targeting trachoma. The project is expected to enable early detection and appropriate treatment for over 100 million people at risk of blindness and vision loss, significantly advancing the global goal of eliminating trachoma. In addition, the GHIT Fund has decided to invest in three product development projects targeting malaria and #Chagas disease. The investments include approximately JPY 150 million (USD 1.0 million) in an antimalarial drug discovery project involving a partnership of Nagasaki University, The University of Tokyo, Shionogi & Co., Ltd ., and Medicines for Malaria Venture ; approximately JPY 70 million (USD 0.49 million) in a rapid diagnostic test development project for Chagas disease involving Nagasaki University, Tulane University , and the Barcelona Institute for Global Health (ISGlobal) ; and approximately JPY 70 million (USD 0.48 million) in a malaria drug discovery project involving The University of Tokyo, MMV, the University of Oxford , and the University of Dundee . Read the full press release 👉 https://lnkd.in/gfh9Zc6y 本日、 #顧みられない熱帯病 （Neglected Tropical Diseases: #NTDs ）および#マラリア に対する診断薬などの製品開発4件に、合計約5.7億円の投資を決定したことを発表いたします。 この度、GHIT Fundは、米国の非営利機関Drugs & Diagnostics for Tropical Diseases (DDTD) が主導し、日本の株式会社#医学生物学研究所 、米国の#カーター・センター とBig Eye Diagnosticsがアメリカ疾病予防管理センター（ #CDC ）の積極的なサポートを得て共同で取り組む#トラコーマ に対する迅速診断検査（RDT）キットの開発プロジェクトに約2.8億円の投資を決定しました。トラコーマに対する製品開発支援はGHIT Fundとして初めてです。本プロジェクトにより、失明や視覚障害のリスクにさらされる1億人以上の人々に対して、早期発見と適切な治療を可能にし、トラコーマ撲滅に向けたグローバルな目標に大きく近づくことが期待されています。 また、マラリアと#シャーガス病 に対する製品開発プロジェクト3件にも投資を決定しました。 (1) 長崎大学、東京大学、 #塩野義製薬 株式会社およびMedicines for Malaria Venture (MMV)による抗マラリア薬開発プロジェクトに約1.5億円、 (2) 長崎大学、米国テュレーン大学、スペインの研究機関Barcelona Institute for Global Health (ISGlobal) によるシャーガス病に対する迅速診断キットの開発プロジェクトに約7,000万円、 (3) 東京大学、MMV、オックスフォード大学、ダンディー大学によるマラリアの治療薬開発プロジェクトに約7,000万円の投資を行います。 詳細はこちら👉 https://lnkd.in/gJ2vW-ET 国立大学法人 長崎大学 Utokyo

✅Proposal seminar video now available The video of the 9th Proposal Writing Seminar, held on October 21st, is now available. If you would like to apply, please check the video for your application and funding opportunities. (Only in Japanese). https://lnkd.in/gta2w-Wd ✅セミナー動画を公開しました 10/21に開催しました『第9回プロポーザル作成セミナー』の動画を公開しました。 RFP（Request for Proposal）に向け、投資（助成）の申請をご検討の皆様は、ぜひ動画をご覧いただき申請書類の作成にお役立てください。 #RFP #Fundingoppotunities #Malaria #TB #NTDs #Chagas #VisceralLeishmaniasis #マラリア #結核 #シャーガス病 #内蔵リーシュマニア症 #公募 #研究開発

💊Now OPEN📣 GHIT Fund announced a new funding opportunity for the three platforms: ●Hit-to-Lead Platform https://lnkd.in/fxZpgTQ ●Product Development Platform https://lnkd.in/fBikQjs ●Target Research Platform https://lnkd.in/fRU9jsQ If you have any questions, please contact us. Also please click the link for investment FAQs👉 https://lnkd.in/gEQpQtpi 💊募集開始📣 2025年度第1回目の公募を開始しました。プログラムへの申請について、詳細は各リンクをご参照ください。 ●ヒット・トゥ・リードプログラム（Hit-to-Lead Platform） https://lnkd.in/gmrcBQrE ●製品開発プログラム（Product Development Platform） https://lnkd.in/gDY-8zU8 ●標的研究プログラム（Target Research Platform） https://lnkd.in/dJ9qikTa 投資についてよくあるご質問はこちらをご覧ください。 https://lnkd.in/gG68N5Nw ＃RFP #Fundingoppotunities #Malaria #TB #NTDs #Chagas #VisceralLeishmaniasis #マラリア #結核 #シャーガス病 #内蔵リーシュマニア症 #公募 #研究開発

🔵Video Series: Innovative Approaches to Combat Schistosomiasis🔵 Combating #Schistosomiasis in #Uganda 📽 We interviewed Dr. Alfred Mubangizi , who oversees all #NTDs , including schistosomiasis, about the current situation and countermeasures for schistosomiasis in Uganda. Please take a look. 📹 https://lnkd.in/g-evfxJN #Schistosomiasis is one of the neglected tropical diseases. While it can be safely and effectively treated in school-aged children and adults, an estimated 50 million preschool-aged children have been left untreated in public health programs primarily due to the lack of an appropriate child-friendly medication. GHIT Fund has supported and invested in the Pediatric Praziquantel Consortium 's development of a new treatment for preschool-aged children since 2013. 🔵 「住血吸虫症との闘い」ビデオシリーズ公開🔵 📽 ウガンダにおける住血吸虫症との闘い📽 ウガンダの保健省で #顧みられない熱帯病 （ #NTD ）対策を統括するアルフレッド・ムバンギジ博士に、公衆衛生上の問題となっている #住血吸虫症 の現状や対策について伺いました。 ウガンダにおける住血吸虫症との闘い📹 https://lnkd.in/g-evfxJN #Schistosomiasis #GlobalHealth #PartnershipsInHealth #ChildrensHealth #PublicPrivatePartnership Merck Group Merck Healthcare アステラス製薬 Farmanguinhos / Fiocruz Lygature Swiss Tropical and Public Health Institute Unlimit Health (formerly SCI Foundation) UNDP

🔵 Video Series: Innovative Approaches to Combat Schistosomiasis🔵 📽 Combating #Schistosomiasis in #Tanzania 📽 We interviewed Dr. Clarer Jones , NTD Program Manager, Ministry of Health, United Republic of Tanzania, about "Combating Schistosomiasis in Tanzania." https://lnkd.in/gZ2qVzb4 ＃Schistosomiasis is one of the neglected tropical diseases. While it can be safely and effectively treated in school-aged children and adults, an estimated 50 million preschool-aged children have been left untreated in public health programs primarily due to the lack of an appropriate child-friendly medication. GHIT Fund has supported and invested in the Pediatric Praziquantel Consortium 's development of a new treatment for preschool-aged children since 2013. 🔵 「住血吸虫症との闘い」ビデオシリーズ公開🔵 📽 タンザニアにおける住血吸虫症との闘い📽 タンザニア保健省 NTDプログラムマネージャーのクララ ジョーンズ ムワンサス氏にタンザニアにおける住血吸虫症の現状や、就学前児童向けの新たな治療選択肢「小児用プラジカンテル」への期待について伺いました。 https://lnkd.in/gZ2qVzb4 #Schistosomiasis #GlobalHealth #PartnershipsInHealth #ChildrensHealth #PublicPrivatePartnership Merck Group , Merck Healthcare , アステラス製薬 , Farmanguinhos / Fiocruz , Lygature , Swiss Tropical and Public Health Institute , Unlimit Health (formerly SCI Foundation) , UNDP

【イベント📝】 GHIT Fundの助成プログラムへの申請書類作成に関する理解を深めて頂くための「プロポーザル作成セミナー」を開催します。研究開発に携わる皆様どうぞ奮ってご参加ください！ ⏰2024/10/21（月）16:30-17:30 （オンライン／参加費 無料／言語 日本語） 申し込みはこちら https://lnkd.in/gU2ZfEEg [Register Now!] GHIT organizes Proposal Writing Seminars (Zoom Webinar) to improve understanding of the application documents required for GHIT investment programs. ⏰Monday, October 21, 2024,16:30-17:30 (JST) (in Japanese only) Learn more https://lnkd.in/gbmaSGzq

We had the honor of hosting our second Global Health Learning Session of the year at our Japan office with Dr. Osamu Kunii , CEO of the Global Health Innovative Technology GHIT Fund and Shingo Iino, Ph.D. , Head of Sustainability at Astellas Pharma Inc. We closely collaborate with both Global Health Innovative Technology (GHIT) Fund and Astellas Pharma in the context of the Pediatric Praziquantel Consortium for a new pediatric treatment option for #schistosomiasis in preschoolers. Using this program as a case study, the importance of public-private partnerships to address global health challenges was in the focus of the session. Our employees enjoyed this informative session, and felt particularly proud of our company’s unwavering commitment and efforts for sustainability and health equity. One of our ambitions is to serve more than 170 million patients per year in low- and middle-income countries by 2030. The elimination of schistosomiasis as a public health problem by 2030 is part of our strategic priorities. Find out more: https://lnkd.in/dN5d8gK Merck Group #Sustainability #HealthEquity #GlobalHealth #EndNTDs

Merck Healthcare

Chagas disease, one of the #NeglectedTropicalDiseases , is endemic mainly in South America, and is estimated to affect around 6–7 million people worldwide. [Interview📹] Dr. Maria Jesus Pinazo "Mother-to-Child Transmission of Chagas Disease" She is speaking on behalf of Drugs for Neglected Diseases initiative - DNDi in support of the project. https://lnkd.in/d4MK8SZX 南米を中心に流行している #顧みられない熱帯 の1つ「シャーガス病」は世界中で約600万～700万人が感染していると言われています。 📹マリア・ヘソソ・ピナソ氏（DNDi シャーガス病疾病戦略責任者）にシャーガス病の母子感染について伺いました。どうぞご覧ください。 https://lnkd.in/dJP8u3dE

Metric
Company Name	GHIT Fund
Symbol
MSH ID	ORG:GHITFUND
Market	PRIVATE
Sector	Healthcare & Health Services
Industry	Public Health
Country	JP
Stage
Employee Count
Website	ghitfund.org
LinkedIn	ghitfund
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

GHIT

ORG:GHITFUND

GHIT Fund

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue